-
Product Insights
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) - Global Clinical Trials Review, 2025" provides an overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) Clinical trials scenario. This report provides top line data relating to the clinical trials on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by...
-
Product Insights
Herpes Zoster (Shingles): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Herpes Zoster (Shingles) - Global Clinical Trials Review, 2025" provides an overview of Herpes Zoster (Shingles) Clinical trials scenario. This report provides top line data relating to the clinical trials on Herpes Zoster (Shingles). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Epilepsy: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Epilepsy - Global Clinical Trials Review, 2025" provides an overview of Epilepsy Clinical trials scenario. This report provides top line data relating to the clinical trials on Epilepsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Focal Segmental Glomerulosclerosis (FSGS: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Focal Segmental Glomerulosclerosis (FSGS) - Global Clinical Trials Review, 2025" provides an overview of Focal Segmental Glomerulosclerosis (FSGS) Clinical trials scenario. This report provides top line data relating to the clinical trials on Focal Segmental Glomerulosclerosis (FSGS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Pustular Psoriasis: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Pustular Psoriasis - Global Clinical Trials Review, 2025" provides an overview of Pustular Psoriasis Clinical trials scenario. This report provides top line data relating to the clinical trials on Pustular Psoriasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Overweight: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Overweight - Global Clinical Trials Review, 2025" provides an overview of Overweight Clinical trials scenario. This report provides top line data relating to the clinical trials on Overweight. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Alopecia Areata Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report deliverables include a PowerPoint report and an Excel-based forecast model and covers the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The base year of the sales forecast model is 2023, and the forecast period is 2023-2033. This report also includes a number of recent enhancement to the forecast models, specifically the US LoA analysis tab and the interactive patient flow tab. The patient flow tab helps to summarize the number of patients treated...
-
Sector Analysis
Idiopathic Pulmonary Fibrosis: Epidemiology Forecast to 2034
Idiopathic pulmonary fibrosis (IPF), a type of interstitial lung disease (ILD), is a serious chronic condition that affects the tissue surrounding the air sacs, or alveoli, in the lungs (National Heart Lung and Blood Institute, 2023). Environmental factors such as smoking, chronic aspiration, or respiratory infections, combined with advancing age, are the likely driving factors for the pathogenesis of IPF by causing respiratory alveolar epithelial injury (Sankari, Chapman and Ullah, 2024). These factors can cause permanent scarring in the lungs,...
-
Sector Analysis
Age-Related Macular Degeneration Epidemiology Analysis and Forecast to 2034
Age-related macular degeneration (AMD) is a chronic, progressive ophthalmological condition characterized by the gradual degeneration of the macula, the specialized area of the retina responsible for high-acuity central vision. It is recognized as the predominant cause of significant and irreversible vision loss among the older demographic. AMD is clinically staged as early, intermediate, and late. Late AMD, representing the advanced phase of the disease, is further subcategorized into late dry AMD (geographic atrophy) and wet AMD (neovascular AMD) (National Eye...
-
Sector Analysis
Dermatophytosis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in dermatophytosis Therapeutics. India is projected to have the highest number of diagnosed prevalent cases of dermatophytosis in both 2024 and 2029, contributing 32.28% and 32.98% of cases, respectively. The dermatophytosis treatment market is largely saturated with generics, with antifungal agents comprising the majority of approved innovator drugs currently available. The pipeline for dermatophytosis remains limited, with no drug in the pre-registration stage, one drug in Phase...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.